CLVS - クロビス・オンコロジ― (Clovis Oncology Inc.) クロビス・オンコロジ―

 CLVSのチャート


 CLVSの企業情報

symbol CLVS
会社名 Clovis Oncology Inc (クロビス・オンコロジ―)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 クロービス・オンコロジー(Clovis Oncology Inc.)は米国、ヨーロッパ及び他の国際市場における抗癌剤の取得・開発・商品化に従事するバイオ医薬品会社である。同社の製品候補にはロシリチニブ、ルブラカ(ルカパリブ)及びルシチニブを含む。ルカパリブは損傷デオキシリボ核酸乳癌(DNA)の修復関連ヒト遺伝子の乳がん(BRCA)突然変異患者の治療向け単剤療法として承認されたPARP1、PARP2及びPARP3の経口小分子ポリアデノシン二リン酸(ADP)・リボースポリメラーゼ(PARP)阻害剤である。ルシチニブは、血管内皮増殖因子受容体(VEGFR)1-3、血小板由来増殖因子受容体(PDGFR)αとβ及び線維芽細胞増殖因子受容体(FGFR)1-3のチロシンキナーゼ活性の経口阻害剤である。ロシリチニブは表皮成長因子受容体(EGFR)の経口突然変異選択的阻害剤である。   クロビス・オンコロジ―は米国のバイオ医薬品会社。抗がん剤の買収、開発、商業化を手掛ける。非小細胞肺がん治療用に経口の選択的・非可逆的EGFR阻害剤CO-186を、また、卵巣がんおよびすい臓がん治療用にポリ(ADP-リボ―ス)ポリメラ―ゼ阻害剤ルカパリブの臨床開発を実施している。   Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.
本社所在地 5500 Flatiron Parkway Suite 100 Boulder CO 80301 USA
代表者氏名 M. James E. Barrett M.ジェームスE.バレット
代表者役職名 Independent Chairman of the Board
電話番号 +1 303-625-5000
設立年月日 39904
市場名 NASDAQ National Market System
ipoyear 2011年
従業員数 360人
url www.clovisoncology.com
nasdaq_url https://www.nasdaq.com/symbol/clvs
adr_tso
EBITDA EBITDA(百万ドル) -268.68600
終値(lastsale) 30.34
時価総額(marketcap) 1597388590.94
時価総額 時価総額(百万ドル) 1531.05
売上高 売上高(百万ドル) 76.12600
企業価値(EV) 企業価値(EV)(百万ドル) 1423.143
当期純利益 当期純利益(百万ドル) -129.23100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Clovis Oncology Inc revenues increased 95% to $42.3M. Net loss decreased 24% to $178.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Legal settlement loss decrease of 93% to $8M (expense) Other income increase from $948K to $2.9M (income).

 CLVSのテクニカル分析


 CLVSのニュース

   Why Is Clovis (CLVS) Down 41.6% Since Last Earnings Report?  2020/03/25 15:30:23 Zacks Investment Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Clovis (CLVS) Q4 Loss Wider Than Expected, Revenues Beat  2020/02/25 09:12:00 Zacks Investment Research
Clovis (CLVS) reports mixed fourth-quarter 2019 results. The company's sole marketed drug, Rubraca, drives revenues. Shares down.
   Clovis Oncology (NASDAQ: CLVS): Q4 2019 Earnings Snapshot  2020/02/24 21:13:28 news.alphastreet.com
— Clovis Oncology (NASDAQ: CLVS) reported a fourth-quarter 2019 loss of $1.81 per share versus a loss of $1.71 per share expected. — Product revenues…
   Clovis Oncology Announces 2019 Operating Results  2020/02/24 21:05:00 Business Wire
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Announces 2019 Operating Results
   Is Clovis Oncology (CLVS) Outperforming Other Medical Stocks This Year?  2020/02/21 16:30:10 Zacks Investment Research
Is (CLVS) Outperforming Other Medical Stocks This Year?
   Clovis (CLVS) Q4 Loss Wider Than Expected, Revenues Beat  2020/02/25 09:12:00 Zacks Investment Research
Clovis (CLVS) reports mixed fourth-quarter 2019 results. The company's sole marketed drug, Rubraca, drives revenues. Shares down.
   Clovis Oncology (NASDAQ: CLVS): Q4 2019 Earnings Snapshot  2020/02/24 21:13:28 news.alphastreet.com
— Clovis Oncology (NASDAQ: CLVS) reported a fourth-quarter 2019 loss of $1.81 per share versus a loss of $1.71 per share expected. — Product revenues…
   Clovis Oncology Announces 2019 Operating Results  2020/02/24 21:05:00 Business Wire
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Announces 2019 Operating Results
   Is Clovis Oncology (CLVS) Outperforming Other Medical Stocks This Year?  2020/02/21 16:30:10 Zacks Investment Research
Is (CLVS) Outperforming Other Medical Stocks This Year?
   Clovis Oncology to Announce Fourth Quarter/Full Year 2019 Financial Results and Host Webcast Conference Call on February 24  2020/02/13 13:30:00 Business Wire
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter and full year 2019 financial results on Monday, February 24, 2020, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the company’s results in greater detail. The conference call is being webcast and can be accessed from the Clovis Oncology website at www.clovisoncology.com. A replay of the webc
   Clovis Oncology to Announce Fourth Quarter/Full Year 2019 Financial Results and Host Webcast Conference Call on February 24  2020/02/13 13:30:00 Business Wire
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter and full year 2019 financial results on Monday, February 24, 2020, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the company’s results in greater detail. The conference call is being webcast and can be accessed from the Clovis Oncology website at www.clovisoncology.com. A replay of the webc
   4 Stocks Looking Higher During Earnings Season  2020/02/06 20:34:06 Benzinga
By Harry Boxer, TheTechTrader Here are three health stocks and one technology stock that are at or near key breakout points: Clovis Oncology, Inc. (NASDAQ: CLVS ) popped 90 cents, or more than 10%, to $9.73 on 11.7 million shares Wednesday on no news. The move edged the stock out of a declining wedge pattern it's been in since its December top. A break through moving average resistance near $10.45 and then the recent double-top at $11.15-.25 could lead the stock to $13 next. 3D Systems Corporation (NYSE: DDD ) climbed 63 cents, or 5.3%, to $12.34 on 2.9 million shares Wednesday. On Monday, the company announced an expanded relationship with Sanmina to manufacture certain … Full story available on Benzinga.com
   Clovis Oncology Is Poised For A Substantial Breakout - StockMatusow  2020/02/04 19:50:15 Seeking Alpha
There's been acquisition rumors associated with this name, but we tend to disregard this rumor but rather, stay focused on what we believe to be an advantageous long trade.
   Clovis Rubraca sNDA for Prostate Cancer Gets Priority Review  2020/01/16 14:09:00 Zacks Investment Research
Clovis' (CLVS) sNDA seeking label expansion of Rubraca to include BRCA-mutant advance prostate cancer gets priority review from the FDA. Stock up.
   FDA Grants Priority Review Designation For Clovis Oncology's Rubraca Label Expansion  2020/01/15 15:22:56 Benzinga Feeds
Clovis Oncology Inc (NASDAQ: CLVS ) shares are advancing strongly after the company clinched a regulatory milestone with respect to its oncology drug Rubraca. The Boulder, Colorado-based biopharma company that focuses on the development of anti-cancer agents said the FDA has accepted its sNDA for rucaparib as a monotherapy for the treatment of adult patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer. Clovis had submitted the regulatory application in November. See Also: The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, … Full story available on Benzinga.com

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 クロビス・オンコロジ― CLVS Clovis Oncology Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)